inclisiran
Showing 1 - 25 of 33
Inclisiran on Major Adverse Cardiovascular Events in French
Not yet recruiting
- Atherosclerotic Cardiovascular Disease
- Inclisiran sodium
- +3 more
- (no location specified)
Jul 26, 2023
Primary Hypercholesterolemia or Mixed Dyslipidemia Trial (Inclisiran, Matching Placebo for Inclisiran)
Not yet recruiting
- Primary Hypercholesterolemia or Mixed Dyslipidemia
- Inclisiran
- Matching Placebo for Inclisiran
- (no location specified)
May 24, 2023
Hypercholesterolemia Trial (Inclisiran, Ezetimibe, Matching Placebo for Inclisiran)
Not yet recruiting
- Hypercholesterolemia
- Inclisiran
- +3 more
- (no location specified)
Feb 28, 2023
Inclisiran Among Early Users in Germany
Completed
- High Levels of Low-density Lipoprotein Cholesterol
-
Basel, SwitzerlandNovartis
May 12, 2023
Primary Prevention of Atherosclerotic Cardiovascular Disease Trial (Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran)
Not yet recruiting
- Primary Prevention of Atherosclerotic Cardiovascular Disease
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Placebo in 1.5ml
- (no location specified)
Feb 13, 2023
The Belgian REAL (BE.REAL) Registry
Not yet recruiting
- Atherosclerotic Cardiovascular Disease
- Inclisiran
- (no location specified)
Feb 3, 2023
Heterozygous or Homozygous Familial Hypercholesterolemia Trial (Inclisiran)
Not yet recruiting
- Heterozygous or Homozygous Familial Hypercholesterolemia
- Inclisiran
- (no location specified)
Dec 27, 2022
German Inclisiran Network: Retrospective Registry of Patients
Recruiting
- Hypercholesterolemia
-
Jena, GermanyJena University Hospital
Jul 4, 2022
Inclisiran Plus Standard of Care Lipid-lowering Therapy Compared
Recruiting
- Primary Hypercholesterolemia
- Mixed Dyslipidemia
- Inclisiran
-
Geneve 14, SwitzerlandNovartis Investigative Site
Nov 14, 2022
Inclisiran in Chinese Adult Primary Hypercholesterolemia or
Recruiting
- Primary Hypercholesterolemia
- Mixed Dyslipidemia
- Inclisiran
-
Haikou, Hainan, China
- +2 more
Jun 13, 2022
Hypercholesterolemia, Atherosclerotic Ischemic Disease Trial in Heidelberg, London (lerodalcibep, Inclisiran)
Enrolling by invitation
- Hypercholesterolemia
- Atherosclerotic Ischemic Disease
- lerodalcibep
- Inclisiran
-
Nantes, Cedex 01, France
- +6 more
Nov 3, 2022
Hyperlipidemia Trial in Changsha, Chengdu, Beijing (100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran), Placebo, 300 mg
Completed
- Hyperlipidemia
- 100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran)
- +2 more
-
Changsha, Hunan, China
- +2 more
Dec 2, 2021
Atherosclerotic Cardiovascular Disease Trial in Boston, Oxford (Inclisiran, Placebo)
Recruiting
- Atherosclerotic Cardiovascular Disease
- Inclisiran
- Placebo
-
Boston, Massachusetts
- +1 more
Mar 1, 2022
Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease Risk Equivelents, Elevated Low Density
Active, not recruiting
- Atherosclerotic Cardiovascular Disease
- +2 more
- Inclisiran
- Behavioural Support
-
Sale, Cheshire, United Kingdom
- +16 more
Jan 20, 2023
Qualitative Features of Atherosclerotic Plaques
Active, not recruiting
- Atherosclerotic Cardiovascular Disease
- Inclisiran
-
Riga, LatviaPauls Stradins Clinical University Hospital
Dec 5, 2022
Atherosclerotic Cardiovascular Disease Trial in United States (Inclisiran)
Recruiting
- Atherosclerotic Cardiovascular Disease
- Inclisiran
-
Little Rock, Arkansas
- +43 more
Jan 20, 2023
LDL-cholesterol Trial in Jena (statins, ezetimibe, bempedoic acid, evolocumab, alirocumab, inclisiran)
Recruiting
- LDL-cholesterol
- statins, ezetimibe, bempedoic acid, evolocumab, alirocumab, inclisiran
-
Jena, Thuringia, GermanyUniversity Hospital Jena
Oct 17, 2022
Hypercholesterolemia, Hypercholesterolemia, Familial Trial in Cambridge (PCSK9 inhibitor, 68Ga-DOTATATE PET-MRI)
Not yet recruiting
- Hypercholesterolemia
- +3 more
- Inclisiran
- +2 more
-
Cambridge, United KingdomUniversity of Cambridge
Jan 13, 2023
sessmenT and treAtment In AustraliaN Primary Care
Not yet recruiting
- Atherosclerotic Cardiovascular Disease (ASCVD)
- +3 more
- Inclisiran Prefilled Syringe
-
Clayton, Victoria, AustraliaMonash Health
Apr 17, 2023
Familial Hypercholesterolemia - Heterozygous Trial in Worldwide (Inclisiran, Placebo)
Recruiting
- Familial Hypercholesterolemia - Heterozygous
- Inclisiran
- Placebo
-
Tucson, Arizona
- +76 more
Aug 8, 2022
Inclisiran and Other Lipid Lowering Treatments inReal-world
Recruiting
- Hypercholesterolemia
- Inclisiran
-
Freudenstadt, Baden Wuerttemberg, Germany
- +94 more
Jan 24, 2023
Coronary Artery Disease Trial in Worldwide (Inclisiran sodium 300 mg, Placebo)
Recruiting
- Coronary Artery Disease
- Inclisiran sodium 300 mg
- Placebo
-
Huntsville, Alabama
- +54 more
Jan 31, 2023
Hypercholesterolemia Trial in Worldwide (inclisiran sodium, Placebo)
Active, not recruiting
- Hypercholesterolemia
- inclisiran sodium
- Placebo
-
Lanzhou, Gansu, China
- +44 more
Feb 7, 2022
Acute Coronary Syndrome Trial in United States (Inclisiran)
Recruiting
- Acute Coronary Syndrome
- Inclisiran
-
Huntsville, Alabama
- +77 more
Jan 13, 2023
Atherosclerotic Cardiovascular Disease, Symptomatic Atherosclerosis, Type2 Diabetes Trial in Worldwide (Inclisiran, Evolocumab)
Completed
- Atherosclerotic Cardiovascular Disease
- +3 more
- Inclisiran
- Evolocumab
-
Jacksonville, Florida
- +51 more
Feb 7, 2022